Skip to main content
Top
Published in: BMC Public Health 1/2023

Open Access 01-12-2023 | Human Papillomavirus | Research

Prevalence and sociodemographic predictors of high-risk vaginal human papillomavirus infection: findings from a public cervical cancer screening registry

Authors: Anis-Syakira Jailani, Nur Zahirah Balqis-Ali, Kar Foong Tang, Weng Hong Fun, Shazimah Abdul Samad, Rohaidza Jahaya, Nurun Najihah Subakir, Roziah Ismail, Zakiah Mohd Said, Sondi Sararaks

Published in: BMC Public Health | Issue 1/2023

Login to get access

Abstract

Introduction

High-risk human papillomavirus (HPV) screening is vital for early cervical cancer detection and treatment. With the introduction of the national cervical cancer screening programme and screening registry in Malaysia, there is a need to monitor population-based HPV screening uptake and high-risk HPV prevalence as part of cervical cancer surveillance.

Objective

To determine the prevalence and sociodemographic factors predicting high-risk HPV infection in Malaysia based on a public, community-based cervical cancer screening registry targeting women at risk of getting HPV infection.

Methods

The study used data from the Malaysian cervical cancer screening registry established by the Family Health Development Division from 2019 to 2021. The registry recorded sociodemographic data, HPV test details and results of eligible women who underwent HPV screening at public primary healthcare facilities. A vaginal sample (via self-sampling or assisted by a healthcare provider) was used for DNA extraction for HPV detection and genotyping. Registry data were extracted and analysed to determine prevalence estimates of high-risk HPV infection. Multifactorial logistic regression analysis was conducted to determine predictors of high-risk HPV infection. All analyses were performed using Stata version 14.

Results

The programme screened a total of 36,738 women during the study period. Women who attended the screening programme were mainly from urban areas, aged 30–39 years, and of Malay ethnicity. The prevalence of high-risk HPV infection was 4.53% among women screened, with the yearly prevalence ranging from 4.27 to 4.80%. A higher prevalence was observed among urban settling women, those aged 30–49 years, those of Indian ethnicity, and those without children. The results from logistic regression showed that women from urban areas, lower age groups, of Indian or Chinese ethnicity, and who are self-employed were more likely to be infected with high-risk HPV.

Conclusion

Targeted and robust strategies to reach identified high-risk groups are needed in Malaysia. In addition, the registry has the potential to be expanded for an improved cervical cancer elimination plan.

Trial registration

Trial registration number: NMRR ID-22-00187-DJU.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2018. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2018.
2.
go back to reference Gravitt PE, Silver MI, Hussey HM, Arrossi S, Huchko M, Jeronimo J, et al. Achieving equity in cervical cancer screening in low-and middle-income countries (LMICs): strengthening health systems using a systems thinking approach. Prev Med. 2021;144:106322.PubMedCrossRef Gravitt PE, Silver MI, Hussey HM, Arrossi S, Huchko M, Jeronimo J, et al. Achieving equity in cervical cancer screening in low-and middle-income countries (LMICs): strengthening health systems using a systems thinking approach. Prev Med. 2021;144:106322.PubMedCrossRef
3.
go back to reference Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the global burden of disease study 2019. BMC Public Health. 2021;21(1):1–10. Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the global burden of disease study 2019. BMC Public Health. 2021;21(1):1–10.
4.
go back to reference Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.PubMedCrossRef Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.PubMedCrossRef
5.
go back to reference Lin S, Gao K, Gu S, You L, Qian S, Tang M, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127(21):4030–9.PubMedCrossRef Lin S, Gao K, Gu S, You L, Qian S, Tang M, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127(21):4030–9.PubMedCrossRef
6.
go back to reference WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization (WHO); 2020. Licence: CC BY-NC-SA 3.0 IGO. WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization (WHO); 2020. Licence: CC BY-NC-SA 3.0 IGO.
7.
go back to reference Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of Cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2022. Supplementary appendix pp 10 & 14. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of Cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2022. Supplementary appendix pp 10 & 14.
8.
go back to reference Azizah A, Hashimah B, Nirmal K, Siti Zubaidah A, Puteri N, Nabihah A, et al. Malaysia national cancer registry report 2012–2016. Malaysia cancer statistics, data and figure. 2019. Azizah A, Hashimah B, Nirmal K, Siti Zubaidah A, Puteri N, Nabihah A, et al. Malaysia national cancer registry report 2012–2016.  Malaysia cancer statistics, data and figure. 2019.
9.
go back to reference Family Health Development Division MoHM. Action plan towards the elimination of cervical cancer in Malaysia 2021–2030. 2021. Family Health Development Division MoHM. Action plan towards the elimination of cervical cancer in Malaysia 2021–2030. 2021.
10.
go back to reference Woo Y. The feasibility and acceptability of self-sampling and HPV testing using Cepheid Xpert® HPV in a busy primary care facility. J Virus Eradication. 2019;5:10–1.CrossRef Woo Y. The feasibility and acceptability of self-sampling and HPV testing using Cepheid Xpert® HPV in a busy primary care facility. J Virus Eradication. 2019;5:10–1.CrossRef
11.
go back to reference Khoo SP, Lim WT, Rajasuriar R, Nasir NH, Gravitt P, Woo YL. The acceptability and preference of vaginal self-sampling for human papillomavirus (HPV) testing among a multi-ethnic asian female population. Cancer Prev Res. 2021;14(1):105–12.CrossRef Khoo SP, Lim WT, Rajasuriar R, Nasir NH, Gravitt P, Woo YL. The acceptability and preference of vaginal self-sampling for human papillomavirus (HPV) testing among a multi-ethnic asian female population. Cancer Prev Res. 2021;14(1):105–12.CrossRef
12.
go back to reference Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. Cost-effectiveness of cervical cancer screening methods in low‐and middle‐income countries: a systematic review. Int J Cancer. 2017;141(3):437–46.PubMedCrossRef Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et al. Cost-effectiveness of cervical cancer screening methods in low‐and middle‐income countries: a systematic review. Int J Cancer. 2017;141(3):437–46.PubMedCrossRef
13.
go back to reference Woo YL, Khoo SP, Gravitt P, Hawkes D, Rajasuriar R, Saville M. The implementation of a primary HPV self-testing cervical screening program in Malaysia through Program ROSE—Lessons Learnt and moving Forward. Curr Oncol. 2022;29(10):7379–87.PubMedPubMedCentralCrossRef Woo YL, Khoo SP, Gravitt P, Hawkes D, Rajasuriar R, Saville M. The implementation of a primary HPV self-testing cervical screening program in Malaysia through Program ROSE—Lessons Learnt and moving Forward. Curr Oncol. 2022;29(10):7379–87.PubMedPubMedCentralCrossRef
14.
go back to reference World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2021. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2021.
15.
go back to reference Family Health Development Division MoHM. Guidelines for primary HPV testing in cervical cancer screening in Malaysia. 2019. Family Health Development Division MoHM. Guidelines for primary HPV testing in cervical cancer screening in Malaysia. 2019.
16.
go back to reference Keane A, Ng CW, Simms K, Nguyen D, Woo Y, Saville M, et al. The road to Cervical cancer elimination in Malaysia: evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support. Int J Cancer. 2021. Keane A, Ng CW, Simms K, Nguyen D, Woo Y, Saville M, et al. The road to Cervical cancer elimination in Malaysia: evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support. Int J Cancer. 2021.
17.
go back to reference Noordzij M, Dekker FW, Zoccali C, Jager KJ. Measures of disease frequency: prevalence and incidence. Nephron Clin Pract. 2010;115(1):c17–20.PubMedCrossRef Noordzij M, Dekker FW, Zoccali C, Jager KJ. Measures of disease frequency: prevalence and incidence. Nephron Clin Pract. 2010;115(1):c17–20.PubMedCrossRef
18.
go back to reference Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.PubMedCrossRef Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.PubMedCrossRef
19.
go back to reference Paengchit K, Kietpeerakool C, Lalitwongsa S. Prevalence and genotype distribution of HPV among women attending a cervical cancer screening mobile unit in Lampang, Thailand. Asian Pac J Cancer Prev. 2014;15(15):6151–4.PubMedCrossRef Paengchit K, Kietpeerakool C, Lalitwongsa S. Prevalence and genotype distribution of HPV among women attending a cervical cancer screening mobile unit in Lampang, Thailand. Asian Pac J Cancer Prev. 2014;15(15):6151–4.PubMedCrossRef
20.
go back to reference Tay SK, Oon LLE. Prevalence of cervical human papillomavirus Infection in healthy women is related to sexual behaviours and educational level: a cross-sectional study. Int J STD AIDS. 2014;25(14):1013–21.PubMedCrossRef Tay SK, Oon LLE. Prevalence of cervical human papillomavirus Infection in healthy women is related to sexual behaviours and educational level: a cross-sectional study. Int J STD AIDS. 2014;25(14):1013–21.PubMedCrossRef
21.
go back to reference Tran LT-H, Tran LT, Bui TC, Le DT-K, Nyitray AG, Markham CM, et al. Risk factors for high-risk and multi-type human papillomavirus Infections among women in Ho Chi Minh City, Vietnam: a cross-sectional study. BMC Womens Health. 2015;15(1):1–9.CrossRef Tran LT-H, Tran LT, Bui TC, Le DT-K, Nyitray AG, Markham CM, et al. Risk factors for high-risk and multi-type human papillomavirus Infections among women in Ho Chi Minh City, Vietnam: a cross-sectional study. BMC Womens Health. 2015;15(1):1–9.CrossRef
22.
go back to reference Khoo SP, Bhoo-Pathy N, Yap SH, Shafii MKA, Nasir NH, Belinson J, et al. Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV) carriage in a cross-sectional, multiethnic, community-based female Asian population. Sex Transm Infect. 2018;94(4):277–83.PubMedCrossRef Khoo SP, Bhoo-Pathy N, Yap SH, Shafii MKA, Nasir NH, Belinson J, et al. Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV) carriage in a cross-sectional, multiethnic, community-based female Asian population. Sex Transm Infect. 2018;94(4):277–83.PubMedCrossRef
23.
go back to reference Othman N, Othman NH. Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev. 2014;15(5):2245–9.PubMedCrossRef Othman N, Othman NH. Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev. 2014;15(5):2245–9.PubMedCrossRef
24.
go back to reference Rahmat F, Kuan JY, Hajiman Z, Shakrin NNSM, Roos NAC, Mustapa M, et al. Human papillomavirus (HPV) prevalence and type distribution in Urban areas of Malaysia. Asian Pac J Cancer Prev. 2021;22(9):2969.PubMedPubMedCentralCrossRef Rahmat F, Kuan JY, Hajiman Z, Shakrin NNSM, Roos NAC, Mustapa M, et al. Human papillomavirus (HPV) prevalence and type distribution in Urban areas of Malaysia. Asian Pac J Cancer Prev. 2021;22(9):2969.PubMedPubMedCentralCrossRef
25.
go back to reference Jaafar S, Noh KM, Muttalib KA, Othman NH, Healy J. Malaysian health system review. 2012. Jaafar S, Noh KM, Muttalib KA, Othman NH, Healy J. Malaysian health system review. 2012.
26.
27.
go back to reference Heideman D, Hesselink A, Berkhof J, Van Kemenade F, Melchers W, Daalmeijer NF, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011;49(11):3983–5.PubMedPubMedCentralCrossRef Heideman D, Hesselink A, Berkhof J, Van Kemenade F, Melchers W, Daalmeijer NF, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011;49(11):3983–5.PubMedPubMedCentralCrossRef
29.
go back to reference Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):1–8.CrossRef Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):1–8.CrossRef
30.
go back to reference Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. 2006. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. 2006.
32.
go back to reference Archer KJ, Lemeshow S. Goodness-of-fit test for a logistic regression model fitted using survey sample data. Stata J. 2006;6(1):97–105.CrossRef Archer KJ, Lemeshow S. Goodness-of-fit test for a logistic regression model fitted using survey sample data. Stata J. 2006;6(1):97–105.CrossRef
33.
go back to reference Anis-Syakira J, Jawahir S, Abu Bakar NS, Mohd Noh SN, Jamalul-Lail NI, Hamidi N, et al. Factors affecting the use of private outpatient services among the adult population in Malaysia. Int J Environ Res Public Health. 2022;19(20):13663.PubMedPubMedCentralCrossRef Anis-Syakira J, Jawahir S, Abu Bakar NS, Mohd Noh SN, Jamalul-Lail NI, Hamidi N, et al. Factors affecting the use of private outpatient services among the adult population in Malaysia. Int J Environ Res Public Health. 2022;19(20):13663.PubMedPubMedCentralCrossRef
34.
go back to reference Institut Kesihatan Umum IKN. National Health Morbidity Survey 2019. Malaysia; 2019. Institut Kesihatan Umum IKN. National Health Morbidity Survey 2019. Malaysia; 2019.
35.
go back to reference Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y, et al. HPV genotype prevalence and distribution during 2009–2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19(1):1–14.CrossRef Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y, et al. HPV genotype prevalence and distribution during 2009–2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19(1):1–14.CrossRef
37.
go back to reference Liu SS, Chan KYK, Leung RCY, Chan KKL, Tam KF, Luk MHM, et al. Prevalence and risk factors of human papillomavirus (HPV) Infection in southern Chinese women–a population-based study. PLoS One. 2011;6(5): e19244.PubMedPubMedCentralCrossRef Liu SS, Chan KYK, Leung RCY, Chan KKL, Tam KF, Luk MHM, et al. Prevalence and risk factors of human papillomavirus (HPV) Infection in southern Chinese women–a population-based study. PLoS One. 2011;6(5): e19244.PubMedPubMedCentralCrossRef
38.
go back to reference Sharifah NA, Seeni A, Nurismah M, Clarence-Ko C, Hatta A, Ho N-P, et al. Prevalence of human papillomavirus in abnormal cervical smears in Malaysian patients. Asian Pac J Cancer Prev. 2009;10(2):303–6.PubMed Sharifah NA, Seeni A, Nurismah M, Clarence-Ko C, Hatta A, Ho N-P, et al. Prevalence of human papillomavirus in abnormal cervical smears in Malaysian patients. Asian Pac J Cancer Prev. 2009;10(2):303–6.PubMed
39.
go back to reference Yi MS, Siang TC, Lwin S, Myint KT, Yee KT, Lwin N, et al. Prevalence of human papilloma virus in women with abnormal cervical smears from sarawak, Malaysia. Res J Pharm Technol. 2021;14(5):2729–34.CrossRef Yi MS, Siang TC, Lwin S, Myint KT, Yee KT, Lwin N, et al. Prevalence of human papilloma virus in women with abnormal cervical smears from sarawak, Malaysia. Res J Pharm Technol. 2021;14(5):2729–34.CrossRef
40.
go back to reference Harano T, Okada S. Prevalence of high-risk human papillomavirus (HR-HPV) Infection among women with normal and abnormal cervical cytology in Myanmar. Acta Med Okayama. 2014;68(2):79–87.PubMed Harano T, Okada S. Prevalence of high-risk human papillomavirus (HR-HPV) Infection among women with normal and abnormal cervical cytology in Myanmar. Acta Med Okayama. 2014;68(2):79–87.PubMed
41.
go back to reference De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.PubMedCrossRef De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.PubMedCrossRef
42.
go back to reference Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184 e1-. e11.CrossRef Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184 e1-. e11.CrossRef
43.
go back to reference Sultana F, English DR, Simpson JA, Brotherton JM, Drennan K, Mullins R, et al. Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never-and under-screened women in Australia. BMC Cancer. 2014;14(1):1–11.CrossRef Sultana F, English DR, Simpson JA, Brotherton JM, Drennan K, Mullins R, et al. Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never-and under-screened women in Australia. BMC Cancer. 2014;14(1):1–11.CrossRef
44.
go back to reference De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.PubMedCrossRef De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.PubMedCrossRef
45.
go back to reference Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7.PubMedCrossRef Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7.PubMedCrossRef
46.
go back to reference Li X, Xiang F, Dai J, Zhang T, Chen Z, Zhang M, et al. Prevalence of cervicovaginal human papillomavirus Infection and genotype distribution in Shanghai, China. Virol J. 2022;19(1):1–9.CrossRef Li X, Xiang F, Dai J, Zhang T, Chen Z, Zhang M, et al. Prevalence of cervicovaginal human papillomavirus Infection and genotype distribution in Shanghai, China. Virol J. 2022;19(1):1–9.CrossRef
47.
go back to reference Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV Infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98(10):1704–9.PubMedPubMedCentralCrossRef Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV Infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98(10):1704–9.PubMedPubMedCentralCrossRef
48.
go back to reference Malaysia DoS. Marriage and divorce statistics, Malaysia. 2020. Malaysia DoS. Marriage and divorce statistics, Malaysia. 2020.
49.
go back to reference Organization WH, Health WHOR, Diseases WHOC, Promotion H. Comprehensive cervical cancer control: a guide to essential practice. Switzerland: World Health Organization; 2006. Organization WH, Health WHOR, Diseases WHOC, Promotion H. Comprehensive cervical cancer control: a guide to essential practice. Switzerland: World Health Organization; 2006.
50.
go back to reference Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical Cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161–9.PubMedCrossRef Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical Cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161–9.PubMedCrossRef
51.
go back to reference Kontula O, Haavio-Mannila E. The impact of aging on human sexual activity and sexual desire. J Sex Res. 2009;46(1):46–56.PubMedCrossRef Kontula O, Haavio-Mannila E. The impact of aging on human sexual activity and sexual desire. J Sex Res. 2009;46(1):46–56.PubMedCrossRef
52.
go back to reference Baloch Z, Yasmeen N, Li Y, Ma K, Wu X, Yang S-h, et al. Prevalence and risk factors for human papillomavirus Infection among Chinese ethnic women in southern of Yunnan, China. Brazilian J Infect Dis. 2017;21:325–32.CrossRef Baloch Z, Yasmeen N, Li Y, Ma K, Wu X, Yang S-h, et al. Prevalence and risk factors for human papillomavirus Infection among Chinese ethnic women in southern of Yunnan, China. Brazilian J Infect Dis. 2017;21:325–32.CrossRef
53.
go back to reference Ilisiu MB, Hashim D, Andreassen T, Støer NC, Nicula F, Weiderpass E. HPV testing for cervical cancer in Romania: high-risk hpv prevalence among ethnic subpopulations and regions. Ann Global Health. 2019;85(1):89.CrossRef Ilisiu MB, Hashim D, Andreassen T, Støer NC, Nicula F, Weiderpass E. HPV testing for cervical cancer in Romania: high-risk hpv prevalence among ethnic subpopulations and regions. Ann Global Health. 2019;85(1):89.CrossRef
54.
go back to reference Akinyemiju T, Ogunsina K, Sakhuja S, Ogbhodo V, Braithwaite D. Life-course socioeconomic status and breast and cervical cancer screening: analysis of the WHO’s study on Global Ageing and Adult Health (SAGE). BMJ Open. 2016;6(11):e012753.PubMedPubMedCentralCrossRef Akinyemiju T, Ogunsina K, Sakhuja S, Ogbhodo V, Braithwaite D. Life-course socioeconomic status and breast and cervical cancer screening: analysis of the WHO’s study on Global Ageing and Adult Health (SAGE). BMJ Open. 2016;6(11):e012753.PubMedPubMedCentralCrossRef
55.
go back to reference Geraets DT, Grünberg AW, van der Helm JJ, van der Loeff MFS, Quint KD, Sabajo LO, et al. Cross-sectional study of genital carcinogenic HPV Infections in Paramaribo, Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-vaccination era. Sex Transm Infect. 2014;90(8):627–33.PubMedCrossRef Geraets DT, Grünberg AW, van der Helm JJ, van der Loeff MFS, Quint KD, Sabajo LO, et al. Cross-sectional study of genital carcinogenic HPV Infections in Paramaribo, Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-vaccination era. Sex Transm Infect. 2014;90(8):627–33.PubMedCrossRef
56.
go back to reference Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus Infection. Obstet Gynecol. 2007;110(1):87–95.PubMedCrossRef Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus Infection. Obstet Gynecol. 2007;110(1):87–95.PubMedCrossRef
57.
go back to reference Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, et al. Prevalence, genotype distribution and risk factors of cervical HPV Infection in Yangqu, China: a population-based survey of 10086 women. Hum Vaccin Immunother. 2020;16(7):1645–52.PubMedCrossRef Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, et al. Prevalence, genotype distribution and risk factors of cervical HPV Infection in Yangqu, China: a population-based survey of 10086 women. Hum Vaccin Immunother. 2020;16(7):1645–52.PubMedCrossRef
58.
go back to reference Bakar NSA, MAnuAl A, Ab HAMid J. Socioeconomic status affecting inequity of healthcare utilisation in Malaysia. Malays J Med Sci. 2019;26(4):79.PubMedPubMedCentral Bakar NSA, MAnuAl A, Ab HAMid J. Socioeconomic status affecting inequity of healthcare utilisation in Malaysia. Malays J Med Sci. 2019;26(4):79.PubMedPubMedCentral
59.
go back to reference Hamidi N, Tan Y, Jawahir S, Tan EH. Determinants of community pharmacy utilisation among the adult population in Malaysia: findings from the National Health and Morbidity Survey 2019. BMC Health Serv Res. 2021;21(1):1–11.CrossRef Hamidi N, Tan Y, Jawahir S, Tan EH. Determinants of community pharmacy utilisation among the adult population in Malaysia: findings from the National Health and Morbidity Survey 2019. BMC Health Serv Res. 2021;21(1):1–11.CrossRef
60.
go back to reference Khoo SP, Muhammad Ridzuan Tan NA, Rajasuriar R, Nasir NH, Gravitt P, Ng CW, et al. Changes in genital human papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program. PLoS One. 2022;17(12):e0278477.PubMedPubMedCentralCrossRef Khoo SP, Muhammad Ridzuan Tan NA, Rajasuriar R, Nasir NH, Gravitt P, Ng CW, et al. Changes in genital human papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program. PLoS One. 2022;17(12):e0278477.PubMedPubMedCentralCrossRef
Metadata
Title
Prevalence and sociodemographic predictors of high-risk vaginal human papillomavirus infection: findings from a public cervical cancer screening registry
Authors
Anis-Syakira Jailani
Nur Zahirah Balqis-Ali
Kar Foong Tang
Weng Hong Fun
Shazimah Abdul Samad
Rohaidza Jahaya
Nurun Najihah Subakir
Roziah Ismail
Zakiah Mohd Said
Sondi Sararaks
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2023
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-023-17132-2

Other articles of this Issue 1/2023

BMC Public Health 1/2023 Go to the issue